Global Peptide Vaccine Market

Peptide Vaccine Comprehensive Study by Type (Biomarkers, NY-ESO-1), Application (Prostate Cancer, Breast Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Others), Rout of Administration (Injected, Other ways), By Therapeutic (Infectious disease, Alzheimer’s disease, Cancer) Players and Region - Global Market Outlook to 2026

Peptide Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Peptide Vaccine Market Scope?
A peptide vaccine is a subunit vaccine based on any peptide that serves to immunize an organism against a pathogen, peptide vaccines are composed of one or more microbial proteinaceous antigens that, when administered, elicit protective immunity against the microbial pathogen.. Peptide vaccines are often synthetic vaccines and mimic naturally occurring proteins from pathogens. In addition to infectious pathogens, peptide vaccines can be utilized as therapeutic cancer vaccines, where peptides from tumor-associated antigens are used to induce an effective anti-tumor T-cell response. According to the research, over 100 million children globally receive vaccinations to prevent diseases that were once widespread and linked to serious medical conditions or even death.

The Peptide Vaccine market study is being classified by Type (Biomarkers and NY-ESO-1), by Application (Prostate Cancer, Breast Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions expansions investments new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Peptide Vaccine market throughout the predicted period.

AFFiRiS (Austria), AlerGenetica(Tracxn Technologies) (India), Anergis(Switzerland), Antigen Express (United States), Apitope Technology (United Kingdom), Araclon Biotech(Spain), Artificial Cell Technologies (United States), Benovus Bio (United States), Bionor Pharma (Norway) and Circassia (Sweden) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ImmunoCellular Therapeutics (United States), Galena Biopharma (Finland) and Immatics biotechnologies (Germany).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Peptide Vaccine market by Type, Application and Region.

On the basis of geography, the market of Peptide Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Increasing government initiatives to improve the health care sector in developing regions

Market Drivers
  • A growing number of cancer cases worldwide
  • The increasing number of infectious diseases across the globe

Opportunities
  • The massive increase in the cost and time span to develop a conventional drug led researchers and pharmaceutical companies to develop new cost-effective products based on synthetic peptide strategy,
  • Cancer immunotherapy by peptide vaccines is one of the most emerging and significant

Restraints
  • High cost and spending on the research process

Challenges
  • They can't be taken orally


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Peptide Vaccine Providers, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Biomarkers
  • NY-ESO-1
By Application
  • Prostate Cancer
  • Breast Cancer
  • Gastric Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others
By Rout of Administration
  • Injected
  • Other ways

By By Therapeutic
  • Infectious disease
  • Alzheimer’s disease
  • Cancer

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A growing number of cancer cases worldwide
      • 3.2.2. The increasing number of infectious diseases across the globe
    • 3.3. Market Challenges
      • 3.3.1. They can't be taken orally
    • 3.4. Market Trends
      • 3.4.1. Increasing government initiatives to improve the health care sector in developing regions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Peptide Vaccine, by Type, Application, Rout of Administration, By Therapeutic and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Peptide Vaccine (Value)
      • 5.2.1. Global Peptide Vaccine by: Type (Value)
        • 5.2.1.1. Biomarkers
        • 5.2.1.2. NY-ESO-1
      • 5.2.2. Global Peptide Vaccine by: Application (Value)
        • 5.2.2.1. Prostate Cancer
        • 5.2.2.2. Breast Cancer
        • 5.2.2.3. Gastric Cancer
        • 5.2.2.4. Lung Cancer
        • 5.2.2.5. Pancreatic Cancer
        • 5.2.2.6. Others
      • 5.2.3. Global Peptide Vaccine by: Rout of Administration (Value)
        • 5.2.3.1. Injected
        • 5.2.3.2. Other ways
      • 5.2.4. Global Peptide Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Peptide Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AFFiRiS (Austria)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AlerGenetica(Tracxn Technologies) (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Anergis(Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Antigen Express (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apitope Technology (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Araclon Biotech(Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Artificial Cell Technologies (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Benovus Bio (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bionor Pharma (Norway)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Circassia (Sweden)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Peptide Vaccine Sale, by Type, Application, Rout of Administration, By Therapeutic and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Peptide Vaccine (Value)
      • 7.2.1. Global Peptide Vaccine by: Type (Value)
        • 7.2.1.1. Biomarkers
        • 7.2.1.2. NY-ESO-1
      • 7.2.2. Global Peptide Vaccine by: Application (Value)
        • 7.2.2.1. Prostate Cancer
        • 7.2.2.2. Breast Cancer
        • 7.2.2.3. Gastric Cancer
        • 7.2.2.4. Lung Cancer
        • 7.2.2.5. Pancreatic Cancer
        • 7.2.2.6. Others
      • 7.2.3. Global Peptide Vaccine by: Rout of Administration (Value)
        • 7.2.3.1. Injected
        • 7.2.3.2. Other ways
      • 7.2.4. Global Peptide Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Peptide Vaccine: by Type(USD Million)
  • Table 2. Peptide Vaccine Biomarkers , by Region USD Million (2015-2020)
  • Table 3. Peptide Vaccine NY-ESO-1 , by Region USD Million (2015-2020)
  • Table 4. Peptide Vaccine: by Application(USD Million)
  • Table 5. Peptide Vaccine Prostate Cancer , by Region USD Million (2015-2020)
  • Table 6. Peptide Vaccine Breast Cancer , by Region USD Million (2015-2020)
  • Table 7. Peptide Vaccine Gastric Cancer , by Region USD Million (2015-2020)
  • Table 8. Peptide Vaccine Lung Cancer , by Region USD Million (2015-2020)
  • Table 9. Peptide Vaccine Pancreatic Cancer , by Region USD Million (2015-2020)
  • Table 10. Peptide Vaccine Others , by Region USD Million (2015-2020)
  • Table 11. Peptide Vaccine: by Rout of Administration(USD Million)
  • Table 12. Peptide Vaccine Injected , by Region USD Million (2015-2020)
  • Table 13. Peptide Vaccine Other ways , by Region USD Million (2015-2020)
  • Table 14. South America Peptide Vaccine, by Country USD Million (2015-2020)
  • Table 15. South America Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 16. South America Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 17. South America Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 18. South America Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 19. Brazil Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 20. Brazil Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 21. Brazil Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 22. Brazil Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 23. Argentina Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 24. Argentina Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 25. Argentina Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 26. Argentina Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 27. Rest of South America Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 30. Rest of South America Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 31. Asia Pacific Peptide Vaccine, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 35. Asia Pacific Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 36. China Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 37. China Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 38. China Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 39. China Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 40. Japan Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 41. Japan Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 42. Japan Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 43. Japan Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 44. India Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 45. India Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 46. India Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 47. India Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 48. South Korea Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 49. South Korea Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 50. South Korea Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 51. South Korea Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 52. Taiwan Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 53. Taiwan Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 54. Taiwan Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 55. Taiwan Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 56. Australia Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 57. Australia Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 58. Australia Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 59. Australia Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 64. Europe Peptide Vaccine, by Country USD Million (2015-2020)
  • Table 65. Europe Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 66. Europe Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 67. Europe Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 68. Europe Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 69. Germany Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 70. Germany Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 71. Germany Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 72. Germany Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 73. France Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 74. France Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 75. France Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 76. France Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 77. Italy Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 78. Italy Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 79. Italy Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 80. Italy Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 81. United Kingdom Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 82. United Kingdom Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 83. United Kingdom Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 84. United Kingdom Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 85. Netherlands Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 86. Netherlands Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 87. Netherlands Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 88. Netherlands Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 89. Rest of Europe Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 90. Rest of Europe Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 91. Rest of Europe Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 92. Rest of Europe Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 93. MEA Peptide Vaccine, by Country USD Million (2015-2020)
  • Table 94. MEA Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 95. MEA Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 96. MEA Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 97. MEA Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 98. Middle East Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 99. Middle East Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 100. Middle East Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 101. Middle East Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 102. Africa Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 103. Africa Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 104. Africa Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 105. Africa Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 106. North America Peptide Vaccine, by Country USD Million (2015-2020)
  • Table 107. North America Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 108. North America Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 109. North America Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 110. North America Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 111. United States Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 112. United States Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 113. United States Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 114. United States Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 115. Canada Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 116. Canada Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 117. Canada Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 118. Canada Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 119. Mexico Peptide Vaccine, by Type USD Million (2015-2020)
  • Table 120. Mexico Peptide Vaccine, by Application USD Million (2015-2020)
  • Table 121. Mexico Peptide Vaccine, by Rout of Administration USD Million (2015-2020)
  • Table 122. Mexico Peptide Vaccine, by By Therapeutic USD Million (2015-2020)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Peptide Vaccine: by Type(USD Million)
  • Table 134. Peptide Vaccine Biomarkers , by Region USD Million (2021-2026)
  • Table 135. Peptide Vaccine NY-ESO-1 , by Region USD Million (2021-2026)
  • Table 136. Peptide Vaccine: by Application(USD Million)
  • Table 137. Peptide Vaccine Prostate Cancer , by Region USD Million (2021-2026)
  • Table 138. Peptide Vaccine Breast Cancer , by Region USD Million (2021-2026)
  • Table 139. Peptide Vaccine Gastric Cancer , by Region USD Million (2021-2026)
  • Table 140. Peptide Vaccine Lung Cancer , by Region USD Million (2021-2026)
  • Table 141. Peptide Vaccine Pancreatic Cancer , by Region USD Million (2021-2026)
  • Table 142. Peptide Vaccine Others , by Region USD Million (2021-2026)
  • Table 143. Peptide Vaccine: by Rout of Administration(USD Million)
  • Table 144. Peptide Vaccine Injected , by Region USD Million (2021-2026)
  • Table 145. Peptide Vaccine Other ways , by Region USD Million (2021-2026)
  • Table 146. South America Peptide Vaccine, by Country USD Million (2021-2026)
  • Table 147. South America Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 148. South America Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 149. South America Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 150. South America Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 151. Brazil Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 152. Brazil Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 153. Brazil Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 154. Brazil Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 155. Argentina Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 156. Argentina Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 157. Argentina Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 158. Argentina Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 159. Rest of South America Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 160. Rest of South America Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 161. Rest of South America Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 162. Rest of South America Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 163. Asia Pacific Peptide Vaccine, by Country USD Million (2021-2026)
  • Table 164. Asia Pacific Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 165. Asia Pacific Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 166. Asia Pacific Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 167. Asia Pacific Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 168. China Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 169. China Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 170. China Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 171. China Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 172. Japan Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 173. Japan Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 174. Japan Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 175. Japan Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 176. India Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 177. India Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 178. India Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 179. India Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 180. South Korea Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 181. South Korea Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 182. South Korea Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 183. South Korea Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 184. Taiwan Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 185. Taiwan Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 186. Taiwan Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 187. Taiwan Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 188. Australia Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 189. Australia Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 190. Australia Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 191. Australia Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 192. Rest of Asia-Pacific Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 196. Europe Peptide Vaccine, by Country USD Million (2021-2026)
  • Table 197. Europe Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 198. Europe Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 199. Europe Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 200. Europe Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 201. Germany Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 202. Germany Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 203. Germany Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 204. Germany Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 205. France Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 206. France Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 207. France Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 208. France Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 209. Italy Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 210. Italy Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 211. Italy Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 212. Italy Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 213. United Kingdom Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 214. United Kingdom Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 215. United Kingdom Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 216. United Kingdom Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 217. Netherlands Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 218. Netherlands Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 219. Netherlands Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 220. Netherlands Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 221. Rest of Europe Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 222. Rest of Europe Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 223. Rest of Europe Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 224. Rest of Europe Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 225. MEA Peptide Vaccine, by Country USD Million (2021-2026)
  • Table 226. MEA Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 227. MEA Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 228. MEA Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 229. MEA Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 230. Middle East Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 231. Middle East Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 232. Middle East Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 233. Middle East Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 234. Africa Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 235. Africa Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 236. Africa Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 237. Africa Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 238. North America Peptide Vaccine, by Country USD Million (2021-2026)
  • Table 239. North America Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 240. North America Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 241. North America Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 242. North America Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 243. United States Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 244. United States Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 245. United States Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 246. United States Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 247. Canada Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 248. Canada Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 249. Canada Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 250. Canada Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 251. Mexico Peptide Vaccine, by Type USD Million (2021-2026)
  • Table 252. Mexico Peptide Vaccine, by Application USD Million (2021-2026)
  • Table 253. Mexico Peptide Vaccine, by Rout of Administration USD Million (2021-2026)
  • Table 254. Mexico Peptide Vaccine, by By Therapeutic USD Million (2021-2026)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Peptide Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Peptide Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Peptide Vaccine: by Rout of Administration USD Million (2015-2020)
  • Figure 7. South America Peptide Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Peptide Vaccine Share (%), by Country
  • Figure 9. Europe Peptide Vaccine Share (%), by Country
  • Figure 10. MEA Peptide Vaccine Share (%), by Country
  • Figure 11. North America Peptide Vaccine Share (%), by Country
  • Figure 12. Global Peptide Vaccine share by Players 2020 (%)
  • Figure 13. Global Peptide Vaccine share by Players (Top 3) 2020(%)
  • Figure 14. Global Peptide Vaccine share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AFFiRiS (Austria) Revenue, Net Income and Gross profit
  • Figure 17. AFFiRiS (Austria) Revenue: by Geography 2020
  • Figure 18. AlerGenetica(Tracxn Technologies) (India) Revenue, Net Income and Gross profit
  • Figure 19. AlerGenetica(Tracxn Technologies) (India) Revenue: by Geography 2020
  • Figure 20. Anergis(Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Anergis(Switzerland) Revenue: by Geography 2020
  • Figure 22. Antigen Express (United States) Revenue, Net Income and Gross profit
  • Figure 23. Antigen Express (United States) Revenue: by Geography 2020
  • Figure 24. Apitope Technology (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Apitope Technology (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Araclon Biotech(Spain) Revenue, Net Income and Gross profit
  • Figure 27. Araclon Biotech(Spain) Revenue: by Geography 2020
  • Figure 28. Artificial Cell Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 29. Artificial Cell Technologies (United States) Revenue: by Geography 2020
  • Figure 30. Benovus Bio (United States) Revenue, Net Income and Gross profit
  • Figure 31. Benovus Bio (United States) Revenue: by Geography 2020
  • Figure 32. Bionor Pharma (Norway) Revenue, Net Income and Gross profit
  • Figure 33. Bionor Pharma (Norway) Revenue: by Geography 2020
  • Figure 34. Circassia (Sweden) Revenue, Net Income and Gross profit
  • Figure 35. Circassia (Sweden) Revenue: by Geography 2020
  • Figure 36. Global Peptide Vaccine: by Type USD Million (2021-2026)
  • Figure 37. Global Peptide Vaccine: by Application USD Million (2021-2026)
  • Figure 38. Global Peptide Vaccine: by Rout of Administration USD Million (2021-2026)
  • Figure 39. South America Peptide Vaccine Share (%), by Country
  • Figure 40. Asia Pacific Peptide Vaccine Share (%), by Country
  • Figure 41. Europe Peptide Vaccine Share (%), by Country
  • Figure 42. MEA Peptide Vaccine Share (%), by Country
  • Figure 43. North America Peptide Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AFFiRiS (Austria)
  • AlerGenetica(Tracxn Technologies) (India)
  • Anergis(Switzerland)
  • Antigen Express (United States)
  • Apitope Technology (United Kingdom)
  • Araclon Biotech(Spain)
  • Artificial Cell Technologies (United States)
  • Benovus Bio (United States)
  • Bionor Pharma (Norway)
  • Circassia (Sweden)
Additional players considered in the study are as follows:
ImmunoCellular Therapeutics (United States) , Galena Biopharma (Finland) , Immatics biotechnologies (Germany)
Select User Access Type

Key Highlights of Report


Apr 2021 202 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Peptide Vaccine Market Quantitative research analysis
Global Peptide Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Peptide Vaccine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Peptide Vaccine market are AFFiRiS (Austria), AlerGenetica(Tracxn Technologies) (India), Anergis(Switzerland), Antigen Express (United States), Apitope Technology (United Kingdom), Araclon Biotech(Spain), Artificial Cell Technologies (United States), Benovus Bio (United States), Bionor Pharma (Norway) and Circassia (Sweden), to name a few.
In this highly competitive & fast evolving Peptide Vaccine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Peptide Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Viral Conjunctivitis Pipeline Drugs Comprehensive Study by Type (Acute Follicular Conjunctivitis Pipeline Drugs, Subacute or Chronic Conjunctivitis Pipeline Drugs), Application (Hospitals, Clinics) P...
$ 3500
Becker Muscular Dystrophy Drug Comprehensive Study by Type (Givinostat, Ataluren, Epicatechin, ARM-210, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2...
$ 3500
Atrial Fibrillation Drugs Comprehensive Study by Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Longstanding Persistent Afib), Drug Class (Calcium Channel Blockers, Beta-Adrene...
$ 3650
Adalimumab Biosimilar Comprehensive Study by Type (Exemptia, Adalirel, Cipleumab, Others), Application (Psoriatic Arthritis, Rheumatoid Arthritis, Other), Distribution Channel (Hospital Pharmacy, Ret...
$ 3350
serratiopeptidase Comprehensive Study by Application (Pharmaceutical & Diagnostics, Research/Biotechnology), Way of ordering (Walk-in, Online) Players and Region - Global Market Outlook to 2027
$ 3500
Iron Drugs Comprehensive Study by Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer Diseases, Others), End User...
$ 3350